METHODS FOR THE TREATMENT OF LUNG DISEASES WITH MAST CELL STABILIZERS
Methods for the treatment of lung diseases with mast cell stabilizers are provided.
1 - 55 . (canceled)
56 . A pharmaceutically acceptable aerosol, comprising droplets of a solution comprising from about 2% to about 6% by weight of cromolyn sodium and an osmolarity adjusting agent consisting of sodium chloride.
57 . The pharmaceutically acceptable aerosol of claim 56 , wherein said solution further comprises purified water and sodium EDTA.
58 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said solution comprises from about 5 mg to about 80 mg of cromolyn sodium.
59 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said solution comprises from about 36 mg to about 44 mg of cromolyn sodium.
60 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said aerosol has a respirable fraction (≦3.3 μm) as measured by USP <1601> of at least about 30%.
61 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said aerosol has a respirable fraction (≦3.3 μm) as measured by USP <1601> of at least about 30% and a respirable fraction (≦5 μm) as measured by USP <1601> of at least about 75%.
62 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said osmolarity adjusting agent consists of between 0.1% to 0.7% sodium chloride, inclusive of the endpoints.
63 . The pharmaceutically acceptable aerosol of claim 56 or 57 , wherein said osmolarity adjusting agent consists of between 0.1% to 0.2% sodium chloride, inclusive of the endpoints.